| Autor: |
Clark, Stephen Michael, Clemmons, Amber B., Schaack, Lindsay, Garren, Jeonifer, DeRemer, David L., Kota, Vamsi K. |
| Předmět: |
|
| Zdroj: |
Journal of Oncology Pharmacy Practice; Jun2016, Vol. 22 Issue 3, p416-422, 7p, 5 Charts |
| Abstrakt: |
Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1–5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
